Comparison · NCT03045406-c9af503d
Apixaban vs Dalteparin: Recurrent Venous Thromboembolism
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Apixaban vs Dalteparin: Recurrent Venous Thromboembolism. Trial comparisons, record NCT03045406-c9af503d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03045406-c9af503d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0556 | 0.0396 | 0.0774 | wilson | |
| Risk in group 2 | 0.0794 | 0.0601 | 0.104 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0239 | -0.0535 | 0.00528 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.699 | 0.452 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 0.682 | 0.427 | 1.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on Apixaban than on Dalteparin | 41.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Apixaban | orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)~Apixaban: Tablets | 32 | 576 | OG000 |
| Group 2 | Dalteparin | subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months~Dalteparin: Injections | 46 | 579 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Recurrent Venous Thromboembolism
- Description
Primary efficacy outcome: objectively confirmed recurrent VTE occurring during the study period, that means the composite of:~· proximal DVT of the lower limbs (symptomatic or unsuspected), DVT of the upper limb (symptomatic), PE (symptomatic or unsuspected)
- Time frame
- 6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
- NCT number
- NCT03045406
- Phases
- PHASE3
- Conditions
- Venous Thromboembolism
- Interventions
- Apixaban, Dalteparin
- Lead sponsor
- Fadoi Foundation, Italy
- Results first posted
- 2025-06-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03045406?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03045406-c9af503d